MGUS and smouldering myeloma
The two stages before multiple myeloma: MGUS is an abnormal antibody in the blood with no symptoms (common and mostly harmless), smouldering myeloma has more abnormal cells but still no organ damage. Both are watched; high-risk smouldering disease is now sometimes treated early.
MGUS is present in about 3% of people over 50 and progresses to myeloma at ~1% per year; smouldering myeloma (≥10% marrow plasma cells or M-protein ≥30 g/L, without CRAB features) progresses at ~10% per year for five years, faster with the 20/2/20 high-risk criteria. The M-protein (paraprotein) and serum free light chains are the measured markers. Lenalidomide (E3A06) and daratumumab (AQUILA, 2024) delay progression in high-risk smouldering disease, prompting debate about treating a pre-cancer; screening for MGUS (iStopMM) is being evaluated in Iceland. Nearly all myeloma passes through MGUS.
Pages like this
not linked directly; found by shared links- TrialCEPHEUS
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- IdeaMRD-guided treatment-free intervals in myeloma
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TrialProtecT
Shares Active surveillance and observation, Active surveillance.
- TermDuctal carcinoma in situ (DCIS)
Shares Active surveillance and observation, Active surveillance.
- TrialMajesTEC-3
Shares Daratumumab, Multiple myeloma.
- TrialPERSEUS
Shares Daratumumab, Lenalidomide, Multiple myeloma.
- TermGleason score and Grade Group
Shares Active surveillance and observation, Active surveillance.
- Key paperMAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant
Shares Daratumumab, Lenalidomide, Multiple myeloma.